ARDELYX INC (ARDX) Stock Fundamental Analysis
USA - NASDAQ:ARDX - US0396971071 - Common Stock
5.42 USD
-0.13 (-2.34%)
5.42 USD
0 (0%)
Taking everything into account, ARDX scores 3 out of 10 in our fundamental rating. ARDX was compared to 533 industry peers in the Biotechnology industry. ARDX may be in some trouble as it scores bad on both profitability and health. ARDX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
ARDX had negative earnings in the past year.
ARDX had a negative operating cash flow in the past year.
ARDX had negative earnings in each of the past 5 years.
ARDX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ARDX (-11.63%) is better than 83.49% of its industry peers.
ARDX has a better Return On Equity (-36.65%) than 73.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.63% | ||
| ROE | -36.65% | ||
| ROIC | N/A |
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARDX has a better Gross Margin (88.21%) than 89.49% of its industry peers.
In the last couple of years the Gross Margin of ARDX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ARDX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
2. Health
2.1 Basic Checks
ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARDX has been increased compared to 1 year ago.
ARDX has more shares outstanding than it did 5 years ago.
ARDX has a worse debt/assets ratio than last year.
2.2 Solvency
ARDX has an Altman-Z score of 0.96. This is a bad value and indicates that ARDX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ARDX (0.96) is better than 64.54% of its industry peers.
A Debt/Equity ratio of 1.31 is on the high side and indicates that ARDX has dependencies on debt financing.
ARDX has a Debt to Equity ratio of 1.31. This is in the lower half of the industry: ARDX underperforms 78.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.31 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.96 |
ROIC/WACCN/A
WACC8.86%
2.3 Liquidity
A Current Ratio of 4.41 indicates that ARDX has no problem at all paying its short term obligations.
ARDX has a Current ratio (4.41) which is comparable to the rest of the industry.
A Quick Ratio of 4.11 indicates that ARDX has no problem at all paying its short term obligations.
The Quick ratio of ARDX (4.11) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 4.11 |
3. Growth
3.1 Past
ARDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.09%, which is quite impressive.
ARDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 58.12%.
ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.15% yearly.
EPS 1Y (TTM)24.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)58.12%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%12.3%
3.2 Future
The Earnings Per Share is expected to grow by 57.52% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.08% on average over the next years. This is a very strong growth
EPS Next Y-93.62%
EPS Next 2Y59.22%
EPS Next 3Y75.14%
EPS Next 5Y57.52%
Revenue Next Year18.36%
Revenue Next 2Y24.77%
Revenue Next 3Y24.45%
Revenue Next 5Y22.08%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARDX. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 62.15, the valuation of ARDX can be described as expensive.
ARDX's Price/Forward Earnings ratio is rather cheap when compared to the industry. ARDX is cheaper than 88.37% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ARDX to the average of the S&P500 Index (34.46), we can say ARDX is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 62.15 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ARDX's earnings are expected to grow with 75.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.22%
EPS Next 3Y75.14%
5. Dividend
5.1 Amount
No dividends for ARDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.42
-0.13 (-2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.15%
Inst Owner Change-11.04%
Ins Owners2.17%
Ins Owner Change5.66%
Market Cap1.31B
Revenue(TTM)398.23M
Net Income(TTM)-56.55M
Analysts87.78
Price Target11.41 (110.52%)
Short Float %8.64%
Short Ratio5.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)70.63%
Min EPS beat(2)41.25%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)104.52%
Min EPS beat(4)-46.66%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)68.73%
EPS beat(12)9
Avg EPS beat(12)555.37%
EPS beat(16)12
Avg EPS beat(16)418.32%
Revenue beat(2)2
Avg Revenue beat(2)12.32%
Min Revenue beat(2)6.56%
Max Revenue beat(2)18.08%
Revenue beat(4)3
Avg Revenue beat(4)5.1%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)18.08%
Revenue beat(8)6
Avg Revenue beat(8)10.55%
Revenue beat(12)10
Avg Revenue beat(12)30.4%
Revenue beat(16)13
Avg Revenue beat(16)26.24%
PT rev (1m)0%
PT rev (3m)1.65%
EPS NQ rev (1m)141.23%
EPS NQ rev (3m)133.14%
EPS NY rev (1m)5.79%
EPS NY rev (3m)23.27%
Revenue NQ rev (1m)3.44%
Revenue NQ rev (3m)3.48%
Revenue NY rev (1m)1.33%
Revenue NY rev (3m)8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 62.15 | ||
| P/S | 3.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.47 | ||
| P/tB | 8.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.23
EYN/A
EPS(NY)0.09
Fwd EY1.61%
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS1.65
BVpS0.64
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.63% | ||
| ROE | -36.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.21% | ||
| FCFM | N/A |
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score5
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.31 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 64.96% | ||
| Cap/Sales | 0.43% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 4.11 | ||
| Altman-Z | 0.96 |
F-Score5
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)26.96%
Cap/Depr(5y)45.67%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-93.62%
EPS Next 2Y59.22%
EPS Next 3Y75.14%
EPS Next 5Y57.52%
Revenue 1Y (TTM)58.12%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%12.3%
Revenue Next Year18.36%
Revenue Next 2Y24.77%
Revenue Next 3Y24.45%
Revenue Next 5Y22.08%
EBIT growth 1Y41.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.62%
EBIT Next 3Y97.39%
EBIT Next 5Y63.08%
FCF growth 1Y18.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.19%
OCF growth 3YN/A
OCF growth 5YN/A
ARDELYX INC / ARDX FAQ
What is the ChartMill fundamental rating of ARDELYX INC (ARDX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ARDX.
What is the valuation status for ARDX stock?
ChartMill assigns a valuation rating of 2 / 10 to ARDELYX INC (ARDX). This can be considered as Overvalued.
How profitable is ARDELYX INC (ARDX) stock?
ARDELYX INC (ARDX) has a profitability rating of 2 / 10.